In patients with suspicious MTC recurrence with serum calcitonin > 150 pg/mL or calcitonin doubling time < 1 year the first line use of [18F]FDOPA allows a detection rate of 66% per patient and 71% per lesion) [52]. This evidence concerns the gene CALCA and medullary thyroid gland carcinoma.